Composite Mineralized Collagen/Polycaprolactone Scaffold-Loaded Microsphere System with Dual Osteogenesis and Antibacterial Functions

Biomaterials play an important role in treating bone defects. The functional characteristics of scaffolds, such as their structure, mechanical strength, and antibacterial and osteogenesis activities, effectively promote bone regeneration. In this study, mineralized collagen and polycaprolactone were used to prepare loaded porous scaffolds with bilayer-structured microspheres with dual antibacterial and osteogenesis functions. The different drug release mechanisms of PLGA and chitosan in PLGA/CS microspheres caused differences in the drug release models in terms of the duration and rate of Pac-525 and BMP-2 release. The prepared PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds were analyzed in terms of physical characteristics, bioactivity, and antibacterial properties. The scaffolds with a dimensional porous structure showed similar porosity and pore diameter to cancellous bone. The release curve of the microspheres and scaffolds with high encapsulation rates displayed the two-stage release of Pac-525 and BMP-2 over 30 days. It was found that the scaffolds could inhibit S. aureus and E. coli and then promote ALP activity. The PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffold could be used as a dual delivery system to promote bone regeneration.


Introduction
Bone replacement surgery is the main therapy used for fracture, tumors, trauma and skeletal infections [1].The autograft and allograft are the two main approaches for bone repair, which have shortcomings include site morbidity, insufficient donors, immune rejection, etc.; as such, the artificial biomaterials that are being widely used for bone defect clinical treatment deserve intensive researched [2].Bone scaffolds are designed to have multiple characteristics, such degradability, porousness, mechanical strength, biocompatibility, and certain biofunctions, which provide the space and stimulation for the proliferation and differentiation of osteocytes [3].Polycaprolactone (PCL), a synthetic biodegradable polymer with high initial mechanical strength and a slow degradation rate, is much easier to fabricate and can be molded into desirable shapes and sizes according to the requirements [4,5].PCL has been processed into various tissue-engineered materials, including being 3D-printed into scaffolds and electrospun into sponges and membranes with PEG [6][7][8].Mineralized collagen (MC) is recognized as an excellent material for promoting osteogenesis, but it lacks sufficient mechanical strength [9][10][11][12][13][14].A PCL matrix Polymers 2024, 16, 2394 2 of 12 containing dispersed MC could constitute an appropriate scaffold for the attachment, proliferation and osteogenic differentiation of mesenchymal stem cells (MSCs) [15].
Additionally, the functional modification of scaffolds by loading bioactive drugs as well as growth factors, stem cells, and antibiotics using advanced technology can improve the osteogenesis, anti-inflammation, and antibacterial abilities of the scaffolds [15].The capability of scaffolds to maintain long-term antibacterial activity is beneficial for treating infective bone defects.Pac-525 (Ac-Lys-Trp-Arg-Arg-Trp-Val-Arg-Trp-Ile-NH 2 ), a synthetic amino acid sequence, has been confirmed to have wide-spectrum antibacterial activity and low drug resistance [16,17].The Val, Ile, Phe, and Trp contained in Pac-525, as rich hydrophobic amino acids, could aid in their insertion deep into the interior of lipopolysaccharide (LPS).The other basic amino acids such as the Lys and Arg in Pac-525 would help neutralize LPS due to their close packing with the phosphate groups or saccharides of LPS [18].Therefore, the antibacterial effects of Pac-525 could avoid the development of bacterial resistance, which is an issue with traditional antibiotics.Bone morphogenetic protein-2 (BMP-2) is one of the most important osteogenic growth factors, having biological activities in osteogenesis and proliferation [19,20].The application of Pac-525 and BMP-2 could allow scaffolds to have dual osteogenesis and antibacterial functions.
It is worth noting that bone regeneration is a long-term process.Considering the situation regarding low local concentration and metabolic loss in vivo, it is necessary to select an appropriate carrier for the local long-term release of drugs [21,22].The present materials used for carriers include natural organic materials, organic polymer materials, inorganic nonmetallic materials, etc. Poly(lactic-co-glycolic acid) (PLGA) is a biodegradable polymer with a long degradation process of up to three months, which helps BMP-2 achieve a long-term osteogenic effect [23,24].Although PLGA shows good biocompatibility and is not cytotoxic, its degradation-induced weak acidic environment poses the potential risk of local inflammation [25].Chitosan (CS) is obtained from the partial deacetylation of chitin, the aqueous solution of which is weakly alkaline, which can balance the local acid-base environment [26].A drug carrier prepared with CS releases Pac-525 in the short term, protecting the bone defect from infection before the release of BMP-2 [27].Therefore, the particles prepared with PLGA and CS could achieve the dual-stage release of BMP-2 and Pac-525 while maintaining biological function.The primary stage of Pac-525 release can guarantee sterile conditions at the site of the bone defect, and the secondary release of BMP-2 can produce a long-term promoting effect on the bone tissue regeneration process.
In this research, we successfully fabricated PLGA (BMP-2) /CS (PAC-525) composite microspheres through electrospraying and crosslinking emulsion methods.The composite microspheres, which exhibited a sphere-in-sphere structure, were assembled in MC/PCL scaffolds to enhance their osteogenic and antibacterial functions.Finally, we investigated the release behavior, physical characteristics, biological viability, and antibacterial capability of the scaffolds, demonstrating their potential for bone regeneration.

PLGA (BMP-2) Microspheres
PLGA microspheres loaded with BMP-2 (PLGA (BMP-2) ) were prepared by electrospraying.Briefly, a certain amount of PLGA was dissolved in methylene chloride under magnetic stirring, obtaining a 60 mg/mL solution.Then, 0.5 mg/mL BMP-2 solution was mixed with PLGA-methylene chloride solution at a volume ratio of 1:40.The mixture was transformed into a water-in-oil (W/O) emulsion through sonication (Scientz-IID, Ningbo Science Biotechnology Co., Ltd., Ningbo, China) on ice at a power of 200 W for 30 s. Subsequently, the emulsion solution was sprayed at a constant flow rate of 1 mL/h using a micro-infusion pump.The voltage applied to the nozzle tip was 6 kV, and the distance between the nozzle tip to the aluminum collection plate was 20 cm.Finally, the PLGA (BMP-2) microspheres were freeze-dried for 24 h to remove the residual solvent.
2.2.2.PLGA (BMP-2) /CS (Pac-525) Composite Microspheres PLGA (BMP-2) /CS (Pac-525) composite microspheres were prepared using the crosslinking emulsification method.Firstly, CS was dissolved in an aqueous acetic acid solution at a dose of 3% (w/v).The prepared PLGA (BMP-2) microspheres and Pac-525 were dispersed in the chitosan solution and stirred magnetically at room temperature.Then, the above mixture was poured into 60 mL of liquid paraffin containing 1.8 mL of Span-80 to form a W/O emulsion, which was stirred magnetically for 30 min at room temperature.Thereafter, a 5% (w/v) aqueous sodium tripolyphosphate (TPP) solution was slowly added to the emulsion to solidify the microspheres.After settling overnight, the obtained PLGA (BMP-2) /CS (Pac-525) composite microspheres were alternately douched with excess amounts of petroleum and isopropyl alcohol three times to clean off the remaining liquid paraffin and Siban-80.Lastly, PLGA (BMP-2) /CS (Pac-525) composite microspheres were lyophilized for 24 h after washing with water.The obtained PLGA/CS microspheres were stored at −20 • C until use.Fluorescein-labeled Nile red (MedChemExpress, Monmouth Junction, NJ, USA) and FITC (Biofroxx, Einhausen, Germany) were used to replace BMP-2 and Pac-525, respectively, in PLGA (Nile) /CS (FITC) composite microspheres with the above methods.2.2.3.PLGA (BMP-2) /CS (Pac-525) @MC/PCL Scaffolds Briefly, PCL powder with a molecular weight of 3 × 10 5 was dissolved in dioxane at a final concentration of 10% (m/v) and stirred gently at room temperature.MC powder was added to the stirred PCL solution at a weight ratio of 1:1 (MC: PCL).After that, the mixture was added into the pores (10 mm diameter and 20 mm height) of the polytetrafluoroethylene mold.Then, 100 mg of the obtained PLGA (BMP-2) /CS (Pac-525) composite microspheres was added into the empty space and mixed thoroughly.Finally, the mold containing the samples was placed in a refrigerator at −20 • C overnight and then freeze-dried for 48 h to remove the dioxane, resulting in a pure PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffold.

Characterization of the Physical and Chemical Properties 2.3.1. Morphology
The morphology of the PLGA (BMP-2) /CS (Pac-525) microspheres and PLGA (BMP-2) / CS (Pac-525) @MC/PCL scaffolds was observed using field-emission scanning electron microscopy (SEM, Merlin Zeiss, Jena, Germany).Microspheres and broken microspheres were dispersed in ethyl alcohol and dropped onto a metal platform for observation.The scaffolds were broken for SEM observation.All the samples were coated with a layer of gold and observed at an accelerating voltage of 10 kV.The fluorescein-labeled PLGA (BMP-2) /CS (Pac-525) microspheres were observed using confocal laser scanning microscopy (CLSM, Zeiss LSM710, Jena, Germany).The size distribution of the microspheres and scaffolds was measured using a Nano Measurer software v1.2.

Encapsulation Rates of Microspheres
The drug encapsulation rates of the PLGA (BMP-2) /CS (Pac-525) microspheres were tested as follows: 20 mg of PLGA/CS microspheres was completely dissolved in a 2% acetic acid solution and then centrifuged at 5000 rpm for 15 min to separate the supernatant (Sp).The precipitate was dried and weighed and then dissolved in acetonitrile (0.7 mL) and 0.01 mol hydrochloric acid buffer (1.3 mL) while stirring.The resulting supernatant (Sb) was centrifuged at a speed of 5000 rpm for 15 min.The concentrations of Pac-525 in Sp and BMP-2 in the Sb were determined using a UV-VIS spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) (280 nm) and a BMP-2 ELISA kit (Abcam, Cambridge, UK), respectively.The determination for each sample group was repeated three times.And the encapsulation rate was calculated using the following formula: The porosity of the scaffold was measured using the fluid displacement method with water (ϱ = 1 g/cm 3 ).Briefly, a sample with a known mass (M1) was placed into a suction bottle containing a certain volume of water.The air from the bottle was then extracted, allowing water to replace the air within the scaffold.Afterwards, the sample was removed, the water on the surface of the scaffold was quickly dried, and the mass (M2) was recorded.The porosity of the scaffold (P) is represented as The compressive strength of the scaffolds was tested using a universal mechanical machine (SHIMADZU AG-IC, Kyoto, Japan) with a 10 kN load cell, applying a compression rate of 0.5 mm/min.The force was applied until the scaffolds underwent a vertical deformation of 30%.Starting from the 20% strain point, the compressive strength was determined by drawing a straight line with the same slope as the elastic modulus and intersecting the curve.The test for each sample group was repeated three times.

Drug Release Test in Vitro
The release behavior of the BMP-2 and Pac-525 from the microspheres and scaffolds was determined as follows: 100 mg of microspheres was soaked in 2 mL of PBS in a shaker at 37 • C. At certain time points, 1 ml of supernatant was collected and supplemented with 1 mL of fresh PBS.For the scaffolds, the scaffolds containing 100 mg of microspheres were placed in 3 mL (V 0 ) of PBS and shaken at 37 • C. At certain time points (n), 1.5 mL (Ve) of supernatant was taken out and replaced with 1.5 mL of fresh PBS.The concentration of Pac-525 (C n−1 ) was measured using a UV-VIS spectrophotometer at 280 nm, while the concentration of BMP-2 was measured using an ELISA kit.M represents the amount of drug in microspheres in Section 2.3.2.The measurement for each sample group was repeated three times.The cumulative release rate (En) was calculated with the following formula: Briefly, bone marrow mesenchymal stem cells (BMSCs) were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco Invitrogen Corporation/Life Technologies Life Sciences, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS, GIBCO Invitrogen Corporation/Life Technologies Life Sciences, Carlsbad, CA, USA) and 100 U/mL penicillin and 100 mg/mL streptomycin [28].The biocompatibility of the scaffolds was proven through the viability of the BMSCs in the samples with a CCK-8 kit (Beyotime Institute of Biotechnology, Jiangsu, China) and cell morphology.The prepared scaffolds were cut into thin slices and sterilized with 60 Co γ-irradiation at a dose of 15 kGy.Then, 1.5 × 10 4 /mL of cells was implanted on sterilized scaffolds in 48-well plates and incubated at 37

Cell Adhesion
For SEM observation, the prepared scaffolds with BMSCs were fixed with 2.5% glutaraldehyde in PBS for 2-3 h.After ethanol gradient dehydration, the samples were freeze-dried and sprayed with gold for SEM observation.
For CLSM observation, the BMSCs were cultured on the scaffolds for 48 h.The samples were taken out from the 48-well plate and fixed with 4% (v/v) paraformaldehyde for 20-30 min.Then, phalloidm-rhodamine (Invitrogen, Carlsbad, CA, USA) was used to stain the cytoplasm of the BMSCs, and DAPI (Sigma-Aldrich Co., LLC., Rockville, MD, USA) was used to stain the nuclei of the BMSCs.The samples were directly observed via CLSM.

Cell Viability
Cell viability was detected with a CCK-8 assay.In brief, BMSCs were cultured in the scaffolds as described above.At the scheduled time points (1, 3, 5 days), the cells were tested with a CCK-8 kit, and the OD value was read using a microplate reader (Bio-Rad, Model 680, Hercules, CA, USA) at 450 nm.All tests were repeated three times.

Detection of Osteogenic Activity
The bioactivity of the BMP-2 released from the microspheres and scaffolds was measured using the alkaline phosphatase (ALP) activity in vitro.After 24 h of culture, the culture medium was replaced with the differentiation medium (DMEM + 10 mmol/L sodium glycerophosphate + 10% FBS + 0.1 mol/L dexamethasone + 50 mg/vitamin C + penicillin and streptomycin), and the supernatant containing the BMP-2 released from the samples was added to the plates.The medium was changed every three days.After 14 days of incubation, BMSCs were lysed with RIPA, and the supernatant was analyzed using the operation of the ALP ELISA kit.The measurement for each sample group was repeated three times.The ALP activity is expressed per microgram (mg) of protein.The total protein in the cell was measured using Pierce™ BCA protein assay kits (Thermo Fisher Scientific Inc., Waltham, MA, USA).

Antibacterial Property of PLGA (BMP-2) /CS (Pac-525) @MC/PCL Scaffolds
An antibacterial cyclome test was used to evaluate the antibacterial activity of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds at different time points (10, 20, 30 days) against S. aureus and E. coli.Briefly, S. aureus and E. coli were cultured in Luria-Bertani (LB) medium at 37 • C overnight.About 1 mL of the sustained-release solution was added to Oxford cups at the scheduled times (10, 20, 30 days).After incubating at 37 • C for 24 h, the size of the inhibition zone was observed to examine the antibacterial activity of the samples.

Statistical Analysis
All of the results are expressed as mean ± standard deviation.The statistical analysis was performed by one-way ANOVA test with SPSS 26.0 software.All data were analyzed at least three times.If p < 0.05, the result was considered to be significantly different.

Morphology of Microspheres and Scaffolds
The PLGA (BMP-2) microspheres prepared by electrospraying were round in shape, with a smooth surface (Figure 1A).The morphology of the PLGA (BMP-2) /CS (Pac-525) microspheres was dense and wrinkled, as shown in Figure 1B.And the PLGA (BMP-2) microspheres were warped and dispersed into the CS shell, forming a sphere-in-sphere structure, as shown in the cross-sections of the PLGA (BMP-2) /CS (Pac-525) and PLGA (Nile) /CS (FITC) microspheres (Figure 1C,D).The composite scaffolds prepared by the freeze-drying method showed an interconnected three-dimensional porous structure that lacked regularity.The PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds presented a porous structure, in which the composite microspheres were evenly distributed in the scaffold, as shown in Figure 1E.Furthermore, on the surface of the scaffolds, there were more microscale structures on the Polymers 2024, 16, 2394 surfaces of the pore walls, possibly due to the addition of MC (Figure 1F).These different sizes of micro-nano surface structures could have increased the surface roughness of the material and then promoted cell adhesion and differentiation [29].
was dense and wrinkled, as shown in Figure 1B.And the PLGA(BMP-2) microspheres were warped and dispersed into the CS shell, forming a sphere-in-sphere structure, as shown in the cross-sections of the PLGA(BMP-2)/CS(Pac-525) and PLGA(Nile)/CS(FITC) microspheres (Figure 1C,D).The composite scaffolds prepared by the freeze-drying method showed an interconnected three-dimensional porous structure that lacked regularity.The PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds presented a porous structure, in which the composite microspheres were evenly distributed in the scaffold, as shown in Figure 1E.Furthermore, on the surface of the scaffolds, there were more microscale structures on the surfaces of the pore walls, possibly due to the addition of MC (Figure 1F).These different sizes of micro-nano surface structures could have increased the surface roughness of the material and then promoted cell adhesion and differentiation [29].

The Drug Release Behaviour in Vitro
As shown in Figure 3A As shown in Table 3, after 30 days of incubation, the cumulative release rates of Pac-525 from the PLGA/CS(Pac-525) microspheres and PLGA/CS(Pac-525)@MC/PCL scaffolds were 66.85 ± 1.04% and 59.42 ± 1.46%, respectively.On the other hand, the cumulative release rates of BMP-2 from the PLGA(BMP-2)/CS microspheres and PLGA(BMP-2)/CS@MC/PCL scaffolds ere 16.26 ± 0.84% and 9.45 ± 1.11%, respectively.Compared with the release of drug-loaded chitosan microspheres mentioned in the literature [34], the interface energy interfered with the release behaviors of Pac-525 and BMP-2 , which made the drug easy to distribute at the interface of PLGA and CS.The release kinetics related to chitosan microspheres were also influenced by the molecular weight and cross-linking degree of chitosan [35].The different release rates of BMP-2 and Pac-525 (Table 3) were caused by the differences in the release mechanisms of the PLGA microspheres and CS microspheres.Due to the hydrophilicity of CS, it is easily infiltrated by body fluids, As shown in Table 3, after 30 days of incubation, the cumulative release rates of Pac-525 from the PLGA/CS (Pac-525) microspheres and PLGA/CS (Pac-525) @MC/PCL scaffolds were 66.85 ± 1.04% and 59.42 ± 1.46%, respectively.On the other hand, the cumulative release rates of BMP-2 from the PLGA (BMP-2) /CS microspheres and PLGA (BMP-2) /CS@MC/PCL scaffolds ere 16.26 ± 0.84% and 9.45 ± 1.11%, respectively.Compared with the release of drug-loaded chitosan microspheres mentioned in the literature [34], the interface energy interfered with the release behaviors of Pac-525 and BMP-2, which made the drug easy to distribute at the interface of PLGA and CS.The release kinetics related to chitosan microspheres were also influenced by the molecular weight and cross-linking degree of chitosan [35].The different release rates of BMP-2 and Pac-525 (Table 3) were caused by the differences in the release mechanisms of the PLGA microspheres and CS microspheres.Due to the hydrophilicity of CS, it is easily infiltrated by body fluids, leading to the rapid release of Pac-525 into tissues.At the same time, the release of BMP-2 proceeds with the degradation of PLGA [36].The drug release kinetics of the BMP-2-loaded PLGA microspheres wrapped in the PLGA (BMP-2) /CS microspheres and PLGA (BMP-2) /CS@/MC/PCL scaffolds were to a large extent affected by the morphologies of the PLGA (BMP-2) /CS microspheres during the process of degradation.For example, the cumulative release rates of the PLGA (BMP-2) /CS microspheres and PLGA (BMP-2) /CS@/MC/PCL scaffolds were only about 13% and 8%, respectively, in the first 10 days, followed by very slow release due to the presence of the chitosan shell.After 30 days, as the shells of the CS and MC/PCL began to crack and lose their integrity, the PLGA microspheres were exposed, leading to a relatively rapid linear release process.This caused two distinct morphological release profiles for BMP-2 and Pac-525.The vitro release kinetics showed that the presence of the scaffold could slow the drug release rate to a certain extent, as shown by comparing the sustained release of PLGA (BMP-2) /CS (Pac-525) microspheres with PLGA (BMP-2) /CS (Pac-525) @/MC/PCL scaffolds.The release curves in Figure 3A,B suggest that the PLGA (BMP-2) /CS (Pac-525) @/MC/PCL scaffolds inhibited infection immediately and promoted long-term osteogenesis.

Biocompatibility
The morphology of the BMSCs adhered to the scaffolds was observed by SEM and CLSM.The BMSCs spread on the surfaces of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds exhibited a well-defined fusiform appearance (Figure 4).Compared to the MC/PCL group, the spread of the cells on the PLGA/CS@MC/PCL and PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds did not seem to be good enough.Then, the viability of the BMSCs was measured using a CCK-8 kit on the first, third, and fifth days.The number of BMSCs increased over time (Figure 5A).Comparing the cell viabilities on PLGA/CS@MC/PCL and PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds to those of the MC/PCL group, there was no significant difference (p value > 0.05).This suggested that the presence of BMP-2 and Pac-525 did not significantly inhibit cell proliferation.It was inferred that the different morphologies of the cells in the MC/PCL group, and in the PLGA/CS@MC/PCL and PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds might have been induced by the more coarse surface structure of the composite microspheres.Nevertheless, the function of BMP-2 was not affected by the preparation of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds.The above results indicated that the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds had a good biological compatibility.

Osteogenic Activity
The osteogenic property of the BMP-2 released from the composite scaffold was determined with an ALP assay kit.As shown in Figure 5B, the ALP activity of the BMSCs in the PLGA(BMP-2)/CS@MC/PCL scaffolds was similar to that of the BMP-2 group, which was significantly higher than that of the other groups.The osteogenic property of the PLGA(BMP-2)/CS(Pac-525)@/MC/PCL scaffolds was significantly improved by BMP-2 in the early stage (Figure 5B) [37].As demonstrated by the sustained release of BMP-2 in Figure difference (p value > 0.05).This suggested that the presence of BMP-2 and Pac-525 did not significantly inhibit cell proliferation.It was inferred that the different morphologies of the cells in the MC/PCL group, and in the PLGA/CS@MC/PCL and PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds might have been induced by the more coarse surface structure of the composite microspheres.Nevertheless, the function of BMP-2 was not affected by the preparation of the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds.The above results indicated that the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds had a good biological compatibility

Osteogenic Activity
The osteogenic property of the BMP-2 released from the composite scaffold was determined with an ALP assay kit.As shown in Figure 5B, the ALP activity of the BMSCs in the PLGA(BMP-2)/CS@MC/PCL scaffolds was similar to that of the BMP-2 group, which was significantly higher than that of the other groups.The osteogenic property of the PLGA(BMP-2)/CS(Pac-525)@/MC/PCL scaffolds was significantly improved by BMP-2 in the early stage (Figure 5B) [37].As demonstrated by the sustained release of BMP-2 in Figure

Osteogenic Activity
The osteogenic property of the BMP-2 released from the composite scaffold was determined with an ALP assay kit.As shown in Figure 5B, the ALP activity of the BMSCs in the PLGA (BMP-2) /CS@MC/PCL scaffolds was similar to that of the BMP-2 group, which was significantly higher than that of the other groups.The osteogenic property of the PLGA (BMP-2) /CS (Pac-525) @/MC/PCL scaffolds was significantly improved by BMP-2 in the early stage (Figure 5B) [37].As demonstrated by the sustained release of BMP-2 in Figure 3A, the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds continuously played a positive role in long-term osteogenesis.

Antimicrobial Activity
In addition to promoting osteogenesis, the antibacterial property of the PLGA (BMP-2) / CS (Pac-525) @/MC/PCL scaffolds was achieved through the incorporation of Pac-525.As shown in Figure 6, the Pac-525 solution released from the scaffolds for 10, 20, and 30 days was used to treat S. aureus and E. coli for 24 h.The antimicrobial activity of the Pac-525 released from the composite scaffold against S. aureus and E. coli was assessed using an antibacterial cyclome test.By observing the size of the antibacterial cyclome, it was found that the samples at 10 days exhibited obvious antibacterial activity.However, compared to the 10-day samples, the diameters of the antibacterial cyclome on both S. aureus and E. coli were much reduced at 20 days.The antibacterial cyclome diameters of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds time-dependently decreased (Table 4).Pac-525 exhibited excellent antibacterial activity against Porphyromonas gingivalis, Fusobacterium nucleatum, S. aureus, and E. coli [38].An antibacterial cyclome formed, indicating the long-term antibacterial activity of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds.The formation of a clear zone around the Oxford cup indicated that the antibacterial property of Pac-525 was not affected by the preparation process.As demonstrated by the sustained release of Pac-525 shown in Figure 3B, the antibacterial function of Pac-525 mainly happened in the first 30 days.Then, the function of the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds was used to promote bone regeneration.To address the problem of resistance to traditional antibiotics, many agents such as metal ions [39,40], lysosomes [41], antimicrobial peptides, and so on, have been investigated.Currently, the mechanism of action of AMPs is still unclear.AMPs might inherently structure with the target and interact with the lipid membrane of the microorganism through electrostatic interactions and receptormediated membrane interactions [42,43].In our previous research, targeting the LPS on Gram-negative bacteria might be one antibacterial mechanism of Pac-525 [18].Overall, the PLGA (BMP-2) /CS (Pac-525) @MC/PCL scaffolds could maintain their antibacterial activity thanks to Pac-525.
was used to treat S. aureus and E. coli for 24 h.The antimicrobial activity of the Pac-525 released from the composite scaffold against S. aureus and E. coli was assessed using an antibacterial cyclome test.By observing the size of the antibacterial cyclome, it was found that the samples at 10 days exhibited obvious antibacterial activity.However, compared to the 10-day samples, the diameters of the antibacterial cyclome on both S. aureus and E. coli were much reduced at 20 days.The antibacterial cyclome diameters of the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds time-dependently decreased (Table 4).Pac-525 exhibited excellent antibacterial activity against Porphyromonas gingivalis, Fusobacterium nucleatum, S. aureus, and E. coli [38].An antibacterial cyclome formed, indicating the long-term antibacterial activity of the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds.The formation of a clear zone around the Oxford cup indicated that the antibacterial property of Pac-525 was not affected by the preparation process.As demonstrated by the sustained release of Pac-525 shown in Figure 3B, the antibacterial function of Pac-525 mainly happened in the first 30 days.Then, the function of the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds was used to promote bone regeneration.To address the problem of resistance to traditional antibiotics , many agents such as metal ions [39,40], lysosomes [41], antimicrobial peptides, and so on, have been investigated.Currently, the mechanism of action of AMPs is still unclear.AMPs might inherently structure with the target and interact with the lipid membrane of the microorganism through electrostatic interactions and receptor-mediated membrane interactions [42,43].In our previous research, targeting the LPS on Gram-negative bacteria might be one antibacterial mechanism of Pac-525 [18].Overall, the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds could maintain their antibacterial activity thanks to Pac-525.
significantly inhibit cell proliferation.It was inferred that the different morphologies of the cells in the MC/PCL group, and in the PLGA/CS@MC/PCL and PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds might have been induced by the more coarse surface structure of the composite microspheres.Nevertheless, the function of BMP-2 was not affected by the preparation of the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds.The above results indicated that the PLGA(BMP-2)/CS(Pac-525)@MC/PCL scaffolds had a good biological compatibility

Table 1 .
Diameter and encapsulation ratio of microspheres.

Table 1 .
Diameter and encapsulation ratio of microspheres.

Table 2 .
Physical characteristics of scaffolds.

Table 3 .
Cumulative release rate of microspheres and scaffolds over 30 days.

Table 4 .
The antibacterial cyclome diameters on E. coli and S. aureus ( # fold change compared with PBS).